HOME >> MEDICINE >> NEWS
NIAID Phase III HIV vaccine trial to determine correlates of protection will not proceed

Phase III trial in Thailand to determine efficacy will be supported by NIAID through a combined NIAID-DoD Program

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the U.S. Army Medical Research and Materiel Command (USAMRMC) of the Department of Defense (DoD), support a broad, comprehensive HIV/AIDS research and development program. Two recent decisions will substantially contribute to a coordinated and comprehensive U.S. government effort to develop preventive HIV vaccines.

DoD HIV Research and Development Program is transferred to NIH

On January 4, 2002, the White House Office of Management and Budget directed the transfer of oversight and management for the DoD HIV Research and Development Program of USAMRMC to the NIH. NIAID, which has the primary responsibility for HIV/AIDS research within the NIH, will assume responsibility for this program beginning October 1, 2002. Both the NIH and USAMRMC are committed to maintaining and building on the various strengths of each program. The Henry M. Jackson Foundation for the Advancement of Military Medicine, a private, non-profit organization that works closely with the Walter Reed Army Institute for Research (WRAIR), a subordinate laboratory of USAMRMC, will be a resource for both programs.

NIAID and USAMRMC have a common goal: to prevent the further spread of HIV/AIDS by developing safe and effective vaccines, other prevention strategies and innovative HIV treatments. The research activities of both groups are complementary and will be effectively integrated. The major difference between the two is the constituencies they serve: the USAMRMC research program primarily serves young, healthy adults on active military duty who are subject to worldwide deployment, while the NIAID research program serves all civilian age groups and addresses all HIV-associated conditions, such as opportunistic
'"/>

Contact: Gregory Roa
greg.roa@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
25-Feb-2002


Page: 1 2 3 4

Related medicine news :

1. NIAID initiates trial of experimental avian flu vaccine
2. NIAID seeks applicants to lead clinical trials units for revamped HIV/AIDS networks
3. NIAID begins enrolling volunteers for novel HIV vaccine study
4. NIAID-sponsored clinical trial aims to boost flu vaccine supply
5. NIAID seeks applicants to lead revamped HIV/AIDS clinical trials networks
6. NIAID launches influenza genome sequencing project
7. NIAID launches program to improve medical tools against emerging infectious diseases
8. NIAID forms network to tackle potentially fatal reaction to smallpox vaccine
9. NIAID rotavirus vaccine licensed for commercialization
10. Second NIAID SARS vaccine candidate helps mice fend off SARS
11. NIAID vaccine protects against SARS virus infection in mice

Post Your Comments:
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, ... vitro fertilization (IVF) -- the incubation of embryos in a ... inside the vagina, new research suggests. Scientists from the ... INVOcell, might sharply cut costs for pricey IVF procedures among ... to those who don,t live near big-city assisted reproduction centers, ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... was diagnosed with Ebola while working for NBC News ... leave the special isolation unit at Nebraska Medical Center in Omaha, ... hospital said Tuesday. A blood test confirmed by the U.S. ... can head home to Providence, R.I., NBC News reported ...
(Date:10/20/2014)... PA (PRWEB) October 20, 2014 Allegheny ... minimally-invasive procedure that enables physicians to repair a damaged ... The MitraClip system, developed by Abbott ... (MR), a progressive and life-threatening condition in which the ... blood to flow backward from the heart’s left ventricle ...
(Date:10/20/2014)... Women’s health specialist, Dr. Amber Murphy, MD, ... Columbus, Inc., A Division of MaternOhio Clinical Associates, Inc., ... 100,000 patients annually. Dr. Murphy will provide a full ... a women’s life. She is accepting new patients at ... Dublin. , Dr. Murphy offers a wide variety of ...
(Date:10/20/2014)... Zereana Jess-Huff, a 34-year-old mother, corporate executive and ... platform to think outside the bra. She doesn’t try to ... raise awareness about women’s other lady parts. , "We have ... the color pink and everybody knows what you’re talking about,” ... it has not been won when it comes to gynecologic ...
Breaking Medicine News(10 mins):Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3
(Date:10/22/2014)... 2014   Surefire Medical , Inc., the developer ... maximize targeted delivery of embolization agents in minimally invasive ... John R. Daniels , MD of the University ... oncologist Steven C. Katz , MD of the ... Advisory Board (SAB).    "The role of ...
(Date:10/22/2014)... Oct. 22, 2014 Provectus Biopharmaceuticals, Inc. (NYSEMKT: ... its novel investigational drug for cancer, is designed for ... side effects. Its oncology focus is on melanoma, breast ... phase 2 trials of PV-10 as a therapy for ... for atopic dermatitis and psoriasis. This ...
(Date:10/20/2014)... Calif. , Oct. 20, 2014  PneumRx, Inc. ... interventional pulmonology, today announced completion of enrollment in their ... RENEW Clinical Study is the FDA-approved IDE pivotal trial ... severe emphysema. It was anticipated that the ... February 2013, would take until the end of 2014 ...
Breaking Medicine Technology:Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3
Cached News: